Kenneth E. S. Poole
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kenneth E. S. Poole has a total of 205 co-authors. Here are the top co-authors by number of shared publications:
- Jonathan Reeve
NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
6 shared publications Andrew H Gee
Department of Public Health and Primary Care , University of Cambridge, Cambridge CB1 8RN, United Kingdom
5 shared publicationsGraham M Treece
Department of Engineering , University of Cambridge, Cambridge CB2 1TN, United Kingdom
5 shared publications- Graham M. Treece
Department of Engineering, University of Cambridge, Cambridge, U.K.
4 shared publications - Nigel Loveridge
Department of Medicine, University of Cambridge, Cambridge, United Kingdom
4 shared publications - Simona D'Amore
Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK
4 shared publications
Latest Publications
- Open Access
- 8 May 2026
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 10 (6)
Midlife risk factors predict long-term hip fracture risk in women: a 35-yr follow-up
Hip fractures in the aging population are a substantial burden for health care. This study investigates whether risk factors presented in midlife could predict long-term hip fracture risk in the coming decades. The study cohort consisted of 11 169 Finnish women who completed a health survey in 1994, establishing the baseline risk factors. These included all FRAX variables except FN BMD. The national registry data was used to identify hip fractures and deaths. The follow-up baseline was set at the age of 55 and was terminated by hip fracture, death, or the end of the follow-up period, whichever occurred first. The follow-up age ranged from 55 to 90 yr, with a mean follow-up time of 29.5 yr (range 0.1-35.0 yr). Long-term risk estimates were performed for each risk factor individually over a cumulative time of 1-yr intervals, using Cox proportional hazard regression models. In total, 801 hip fractures were observed during the 35 yr. Several midlife risk factors appear to sustain their relevance later in life, predicting long-term hip fracture risk in women. The significant risk factors included (hazard ratio minimum to maximum) previous fracture (HR 1.5-4.4), parental hip fracture (HR 1.3-2.8), regular smoking (HR 1.8-4.1), glucocorticoid use (HR 1.7-5.3), rheumatoid arthritis (HR 2.2-4.8), poor self-reported health (HR 1.0-4.3), and polypharmacy (HR 1.1-2.7). The findings suggest that several risk factors identified in midlife demonstrate persistent associations with the long-term risk of hip fractures. Early detection and prevention of these factors may help to reduce the risk in later life.
- 8 May 2026
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 10 (6)
Open AccessMidlife risk factors predict long-term hip fracture risk in women: a 35-yr follow-up
Hip fractures in the aging population are a substantial burden for health care. This study investigates whether risk factors presented in midlife could predict long-term hip fracture risk in the coming decades. The study cohort consisted of 11 169 Finnish women who completed a health survey in 1994, establishing the baseline risk factors. These included all FRAX variables except FN BMD. The national registry data was used to identify hip fractures and deaths. The follow-up baseline was set at the age of 55 and was terminated by hip fracture, death, or the end of the follow-up period, whichever occurred first. The follow-up age ranged from 55 to 90 yr, with a mean follow-up time of 29.5 yr (range 0.1-35.0 yr). Long-term risk estimates were performed for each risk factor individually over a cumulative time of 1-yr intervals, using Cox proportional hazard regression models. In total, 801 hip fractures were observed during the 35 yr. Several midlife risk factors appear to sustain their relevance later in life, predicting long-term hip fracture risk in women. The significant risk factors included (hazard ratio minimum to maximum) previous fracture (HR 1.5-4.4), parental hip fracture (HR 1.3-2.8), regular smoking (HR 1.8-4.1), glucocorticoid use (HR 1.7-5.3), rheumatoid arthritis (HR 2.2-4.8), poor self-reported health (HR 1.0-4.3), and polypharmacy (HR 1.1-2.7). The findings suggest that several risk factors identified in midlife demonstrate persistent associations with the long-term risk of hip fractures. Early detection and prevention of these factors may help to reduce the risk in later life.
- Open Access
- 27 December 2025
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 41 (9) , 963-971
The clinical utility of imaging in osteoarthritis and its importance in future prediction of total hip replacement; a nested case-control study within the AGES-Reykjavik cohort
Current guidelines are split on the role that imaging has in the clinical assessment of osteoarthritis (OA), yet clinical CT imaging has now revealed how a 3D approach can improve prediction of TH replacement (THR) over 2D measures alone. We applied 2D grading and measurement along with 3D cortical bone mapping to ordinary clinical CT imaging of the pelvis in a cohort of healthy older people, aiming to discover which of these features had clinical utility in predicting THR within 8 yr and which were related to baseline hip pain. Using a nested case-control design in the Age, Gene/Environment Susceptibility-Reykjavik (AGES-Reykjavik) study, 74 future THR cases were age and sex-matched with 184 controls from the cohort (age 74 ± 5 yr). Baseline assessment involved a validated hip pain questionnaire and pelvic CT. The following were performance-tested using receiver operating characteristics analysis and clinical utility index: (1) hip pain, (2) Kellgren and Lawrence grade (K&L grade), (3) minimum joint space width, and (4) 3D cortical bone thickness (CTh). The clinical utility index for prediction of future THR from baseline pain was poor at 0.28, with the inclusion of imaging improving this to 0.79 (K&L grade) and 0.82 (3D CTh). Self-reported hip pain at baseline was also a poor-to-marginal predictor of THR (AUC = 0.63), but 3D cortical thickening at the femoral head was predictive of future THR (0.81). Having radiographic OA strongly predicted THR irrespective of hip pain (0.85). Combining hip pain, K&L grade, and 3D CTh gave optimal prediction (0.88). Ascertainment bias may have occurred, if primary care physicians requested their own radiographs of their patients’ hips. Imaging features from standard clinical CT identifies patients at high risk of progression to surgery for OA, regardless of baseline pain.
- 27 December 2025
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 41 (9) , 963-971
Open AccessThe clinical utility of imaging in osteoarthritis and its importance in future prediction of total hip replacement; a nested case-control study within the AGES-Reykjavik cohort
Current guidelines are split on the role that imaging has in the clinical assessment of osteoarthritis (OA), yet clinical CT imaging has now revealed how a 3D approach can improve prediction of TH replacement (THR) over 2D measures alone. We applied 2D grading and measurement along with 3D cortical bone mapping to ordinary clinical CT imaging of the pelvis in a cohort of healthy older people, aiming to discover which of these features had clinical utility in predicting THR within 8 yr and which were related to baseline hip pain. Using a nested case-control design in the Age, Gene/Environment Susceptibility-Reykjavik (AGES-Reykjavik) study, 74 future THR cases were age and sex-matched with 184 controls from the cohort (age 74 ± 5 yr). Baseline assessment involved a validated hip pain questionnaire and pelvic CT. The following were performance-tested using receiver operating characteristics analysis and clinical utility index: (1) hip pain, (2) Kellgren and Lawrence grade (K&L grade), (3) minimum joint space width, and (4) 3D cortical bone thickness (CTh). The clinical utility index for prediction of future THR from baseline pain was poor at 0.28, with the inclusion of imaging improving this to 0.79 (K&L grade) and 0.82 (3D CTh). Self-reported hip pain at baseline was also a poor-to-marginal predictor of THR (AUC = 0.63), but 3D cortical thickening at the femoral head was predictive of future THR (0.81). Having radiographic OA strongly predicted THR irrespective of hip pain (0.85). Combining hip pain, K&L grade, and 3D CTh gave optimal prediction (0.88). Ascertainment bias may have occurred, if primary care physicians requested their own radiographs of their patients’ hips. Imaging features from standard clinical CT identifies patients at high risk of progression to surgery for OA, regardless of baseline pain.
- Open Access
- 11 September 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 33 (12) , 1511-1521
Knee osteoarthritis bone shape from computed tomography is associated with subchondral bone attenuation and marginal cortical bone thickness: A cross-sectional study
- 11 September 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 33 (12) , 1511-1521
Open AccessKnee osteoarthritis bone shape from computed tomography is associated with subchondral bone attenuation and marginal cortical bone thickness: A cross-sectional study
- Open Access
- 4 September 2025
- Published by Springer Nature in Current Osteoporosis Reports
- Vol. 23 (1) , 1-13
Pathophysiology of Femoral Fractures in Hypophosphatasia
Purpose of Review: In this review, we will examine the pathophysiology, anatomy, biochemistry, and genotype-phenotype correlation of femoral fractures in adult hypophosphatasia. Recent Findings: Hypophosphatasia (HPP) is a rare genetic disease characterized by low activity of tissue-nonspecific alkaline phosphatase (TNAP). The disease presents a broad spectrum of clinical manifestations primarily determined by the degree of residual TNAP activity. Adults with HPP of moderate clinical severity may present with spontaneous femoral fractures that are like the atypical femoral fractures (AFF) of long-term bisphosphonates users. In this review, we will focus on the paradox that while HPP can cause biopsy-proven osteomalacia (pathologically impaired bone mineralisation), the spontaneous femoral fractures that characterise adult HPP do not exhibit typical osteomalacia features. Instead, they resemble the femoral fractures that occur in other diseases such as osteopetrosis where bone becomes excessively dense, brittle and highly mineralised due to osteoclast dysfunction. Summary: This review examines the key aspects of the pathophysiology of femoral fractures in adults with HPP, offering new insights into the role of anatomical, molecular and biochemical bone abnormalities that characterise the disease. Further investigations of HPP patients with femoral fracture are needed to examine the nanoscale crystal structure of the bone and to study abnormalities in fracture healing and bone resorption.
- 4 September 2025
- Published by Springer Nature in Current Osteoporosis Reports
- Vol. 23 (1) , 1-13
Open AccessPathophysiology of Femoral Fractures in Hypophosphatasia
Purpose of Review: In this review, we will examine the pathophysiology, anatomy, biochemistry, and genotype-phenotype correlation of femoral fractures in adult hypophosphatasia. Recent Findings: Hypophosphatasia (HPP) is a rare genetic disease characterized by low activity of tissue-nonspecific alkaline phosphatase (TNAP). The disease presents a broad spectrum of clinical manifestations primarily determined by the degree of residual TNAP activity. Adults with HPP of moderate clinical severity may present with spontaneous femoral fractures that are like the atypical femoral fractures (AFF) of long-term bisphosphonates users. In this review, we will focus on the paradox that while HPP can cause biopsy-proven osteomalacia (pathologically impaired bone mineralisation), the spontaneous femoral fractures that characterise adult HPP do not exhibit typical osteomalacia features. Instead, they resemble the femoral fractures that occur in other diseases such as osteopetrosis where bone becomes excessively dense, brittle and highly mineralised due to osteoclast dysfunction. Summary: This review examines the key aspects of the pathophysiology of femoral fractures in adults with HPP, offering new insights into the role of anatomical, molecular and biochemical bone abnormalities that characterise the disease. Further investigations of HPP patients with femoral fracture are needed to examine the nanoscale crystal structure of the bone and to study abnormalities in fracture healing and bone resorption.
- Open Access
PHOENIX-f: A Randomised Controlled Feasibility Study of One-Stop Osteoporosis Screening among Patients Undergoing Routine Computed Tomography using FRAX and CliniQCT Bone Density Measurement and Vertebral Fracture Detection
The PHOENIX-f (Picking up Hidden Osteoporosis Effectively during Normal CT Imaging without additional X-rays) feasibility study determined the future evaluability of one-stop osteoporosis screening in patients undergoing computed tomography (CT) scans relating to other conditions. To improve identification and treatment rates amongst higher fracture risk older patients, we conducted a feasibility randomised controlled trial to help plan a definitive trial. We sought to determine ability to randomise and collect follow-up measures. We further sought to estimate this population’s osteoporosis and vertebral fracture prevalence, and treatment rates. In one teaching hospital and four regional UK hospital radiology waiting areas, patients undergoing abdomen ± pelvis CT scans (women aged ≥65, men aged ≥75) areas were offered ‘FRAX’ fracture risk questionnaires with embedded consent forms for voluntary completion. Consenting patients identified as having moderate/high 10-year fracture risk based on initial screening (FRAX red/amber zones) were randomised (1:1:1) to: 1) CliniQCT One-Stop osteoporosis screening pathway (vertebral fracture assessment and hip/spine BMD measurement by applying Mindways QCT and SlicePick-MT software to CT scans, plus algorithm-based recommendations sent by electronic letter to general practitioners (GPs); 2) FRAX answers sent to GPs; 3) usual care (GP informed of participation). Co-primary feasibility endpoints were to randomise 375 patients within 10 months and retain 75% of survivors for a 1-year bone health outcome questionnaire. From 1,828 eligible for invitation, 595 participants consented; low FRAX scores excluded 213 patients. Outcomes achieved included randomising 382 patients within 10 months and 284/329 survivors (86%) completing 1-year follow-up. Of 356 analysable CT scans osteoporosis was diagnosed in 42%. 46/258 (18%) whole thoraco-lumbar scans showed vertebral fractures. At follow-up 36%, 26% and 8% of patients needing osteoporosis treatment in the screened, FRAX-only and usual care groups respectively reported taking treatment. Suggested benefits of the CliniQCT screening pathway warrant further effectiveness and cost-effectiveness evaluation. Lay summary Whole body CT scanners are frequently used to find and track various diseases. We tested a new treatment pathway that re-uses scans to additionally spot people with weak bones (osteoporosis) or broken bones in the spine – where seen, GPs are told and given advice about treatment. To see if we could comprehensively test this new pathway in future, we conducted a ‘feasibility study’ comparing it to current forms of treatment. Good numbers of people of people joined the study and kept returning questionnaires. This suggests a future study testing how well the pathway works, and how costs compare, is achievable.
Open AccessPHOENIX-f: A Randomised Controlled Feasibility Study of One-Stop Osteoporosis Screening among Patients Undergoing Routine Computed Tomography using FRAX and CliniQCT Bone Density Measurement and Vertebral Fracture Detection
The PHOENIX-f (Picking up Hidden Osteoporosis Effectively during Normal CT Imaging without additional X-rays) feasibility study determined the future evaluability of one-stop osteoporosis screening in patients undergoing computed tomography (CT) scans relating to other conditions. To improve identification and treatment rates amongst higher fracture risk older patients, we conducted a feasibility randomised controlled trial to help plan a definitive trial. We sought to determine ability to randomise and collect follow-up measures. We further sought to estimate this population’s osteoporosis and vertebral fracture prevalence, and treatment rates. In one teaching hospital and four regional UK hospital radiology waiting areas, patients undergoing abdomen ± pelvis CT scans (women aged ≥65, men aged ≥75) areas were offered ‘FRAX’ fracture risk questionnaires with embedded consent forms for voluntary completion. Consenting patients identified as having moderate/high 10-year fracture risk based on initial screening (FRAX red/amber zones) were randomised (1:1:1) to: 1) CliniQCT One-Stop osteoporosis screening pathway (vertebral fracture assessment and hip/spine BMD measurement by applying Mindways QCT and SlicePick-MT software to CT scans, plus algorithm-based recommendations sent by electronic letter to general practitioners (GPs); 2) FRAX answers sent to GPs; 3) usual care (GP informed of participation). Co-primary feasibility endpoints were to randomise 375 patients within 10 months and retain 75% of survivors for a 1-year bone health outcome questionnaire. From 1,828 eligible for invitation, 595 participants consented; low FRAX scores excluded 213 patients. Outcomes achieved included randomising 382 patients within 10 months and 284/329 survivors (86%) completing 1-year follow-up. Of 356 analysable CT scans osteoporosis was diagnosed in 42%. 46/258 (18%) whole thoraco-lumbar scans showed vertebral fractures. At follow-up 36%, 26% and 8% of patients needing osteoporosis treatment in the screened, FRAX-only and usual care groups respectively reported taking treatment. Suggested benefits of the CliniQCT screening pathway warrant further effectiveness and cost-effectiveness evaluation. Lay summary Whole body CT scanners are frequently used to find and track various diseases. We tested a new treatment pathway that re-uses scans to additionally spot people with weak bones (osteoporosis) or broken bones in the spine – where seen, GPs are told and given advice about treatment. To see if we could comprehensively test this new pathway in future, we conducted a ‘feasibility study’ comparing it to current forms of treatment. Good numbers of people of people joined the study and kept returning questionnaires. This suggests a future study testing how well the pathway works, and how costs compare, is achievable.
- Open Access
- 26 March 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (5) , 2429-2444
Mobility and Quality of Life in Adults with Paediatric-Onset Hypophosphatasia Treated with Asfotase Alfa: Results from UK Managed Access Agreement
Introduction Hypophosphatasia (HPP) is a rare disease caused by deficient tissue–non-specific alkaline phosphatase (ALP) activity. Asfotase alfa is a tissue–non-specific ALP enzyme-replacement therapy which was reimbursed in the UK under a Managed Access Agreement (MAA). This analysis assessed safety and effectiveness of asfotase alfa in adults with HPP. Methods This prospective, observational data collection included adults with paediatric-onset HPP enroled in the MAA and treated with asfotase alfa for ≥ 6 months to 5 years. Assessments included mobility, pain, and health-related quality of life (HRQoL), each reported at regular intervals through year 3. Analgesic use, fractures, and events of interest (EOIs) were each reported continuously throughout follow-up. Results Of 28 enroled treated adults, 24 were assessed for effectiveness. Distance walked in the 6-Minute Walk Test was median (min, max) 172.5 m (0.0, 380.0; n = 24) at baseline and improved by 157.3 m (− 171.0, 479.5; n = 16) at month 6; results were sustained throughout follow-up. Median (min, max) Bleck score was 6.0 (2.0, 9.0; n = 24) at baseline and increased to 6.5 (5.0, 9.0; n = 10) at month 36. Median (min, max) aggregate Brief Pain Inventory Short Form severity score was 8.0 (4.3, 10.0; n = 24) at baseline and improved to 4.4 (1.0, 7.8; n = 10) at month 36. During follow-up, 8 participants (33.3%) decreased or discontinued opioid use throughout follow-up and 4 (16.7%) reported fractures. Median (min, max) EQ-5D-3L utility scores improved from 0.21 (− 0.26, 0.60; n = 24) at baseline by 0.15 (− 0.36, 0.91; n = 24) at month 6 and were similar throughout follow-up. Injection site reactions were the most common treatment-related EOI, reported in 17 participants (60.7%). Three participants reported treatment-related serious adverse events. Conclusion Asfotase alfa treatment improved mobility, physical function, pain, and HRQoL and was well tolerated. These data show the benefit of asfotase alfa in adults with paediatric-onset HPP.
- 26 March 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (5) , 2429-2444
Open AccessMobility and Quality of Life in Adults with Paediatric-Onset Hypophosphatasia Treated with Asfotase Alfa: Results from UK Managed Access Agreement
Introduction Hypophosphatasia (HPP) is a rare disease caused by deficient tissue–non-specific alkaline phosphatase (ALP) activity. Asfotase alfa is a tissue–non-specific ALP enzyme-replacement therapy which was reimbursed in the UK under a Managed Access Agreement (MAA). This analysis assessed safety and effectiveness of asfotase alfa in adults with HPP. Methods This prospective, observational data collection included adults with paediatric-onset HPP enroled in the MAA and treated with asfotase alfa for ≥ 6 months to 5 years. Assessments included mobility, pain, and health-related quality of life (HRQoL), each reported at regular intervals through year 3. Analgesic use, fractures, and events of interest (EOIs) were each reported continuously throughout follow-up. Results Of 28 enroled treated adults, 24 were assessed for effectiveness. Distance walked in the 6-Minute Walk Test was median (min, max) 172.5 m (0.0, 380.0; n = 24) at baseline and improved by 157.3 m (− 171.0, 479.5; n = 16) at month 6; results were sustained throughout follow-up. Median (min, max) Bleck score was 6.0 (2.0, 9.0; n = 24) at baseline and increased to 6.5 (5.0, 9.0; n = 10) at month 36. Median (min, max) aggregate Brief Pain Inventory Short Form severity score was 8.0 (4.3, 10.0; n = 24) at baseline and improved to 4.4 (1.0, 7.8; n = 10) at month 36. During follow-up, 8 participants (33.3%) decreased or discontinued opioid use throughout follow-up and 4 (16.7%) reported fractures. Median (min, max) EQ-5D-3L utility scores improved from 0.21 (− 0.26, 0.60; n = 24) at baseline by 0.15 (− 0.36, 0.91; n = 24) at month 6 and were similar throughout follow-up. Injection site reactions were the most common treatment-related EOI, reported in 17 participants (60.7%). Three participants reported treatment-related serious adverse events. Conclusion Asfotase alfa treatment improved mobility, physical function, pain, and HRQoL and was well tolerated. These data show the benefit of asfotase alfa in adults with paediatric-onset HPP.
- Open Access
- 7 November 2024
- Published by MDPI AG in Metabolites
- Vol. 14 (11) , 601
Changes in Angiogenesis and Bone Turnover Markers in Patients with Gaucher Disease Developing Osteonecrosis
Background/Objectives: Patients with Gaucher disease have a high risk of bone disease, with osteonecrosis representing the most debilitating complication. The pathogenesis of osteonecrosis has not been fully elucidated yet, and there is an unmet need for predictive biomarkers of bone complications. We aimed to assess the utility of angiogenesis and bone turnover biomarkers as predictors of osteonecrosis in Gaucher disease. Methods: Angiogenesis and bone turnover biomarkers were measured in 146 Gaucher disease patients (70M:76F, median age 49.5 [IQR 36.7 to 61]) with/without osteonecrosis enrolled in the UK-based registry GAUCHERITE [enrolment 2015–2017]. Receiver-operating characteristic curve analysis was used to compare the osteonecrosis predictive value of angiogenesis and bone turnover biomarkers and determine the optimal cut-off values for each biomarker. Results: Sixty-two patients had osteonecrosis before study enrolment, 11 had osteonecrosis during follow-up, and 73 remained osteonecrosis-free. Patients with osteonecrosis showed increased osteopontin and matrix metalloproteinase (MMP)-2 levels and decreased MMP-9 and vascular endothelial growth factor (VEGF)-C compared with those free from osteonecrosis. MMP-9 predicted future osteonecrosis with higher sensitivity and specificity (area under the receiver operating characteristic curve [AUC] 0.84 [95% CI 0.84–0.99]; sensitivity/specificity 82%/75%; cutoff value ≤ 72,420 pg/mL) than osteopontin, MMP-2 and VEGF-C when taken alone. The combination of MMP-9 and VEGF-C further increased the discriminating accuracy. Conclusions: The osteopontin–MMPs–VEGF axis is dysregulated in Gaucher disease patients with osteonecrosis. The combination of MMP-9 and VEGF-C circulating levels may serve to identify Gaucher disease patients at risk of osteonecrosis.
- 7 November 2024
- Published by MDPI AG in Metabolites
- Vol. 14 (11) , 601
Open AccessChanges in Angiogenesis and Bone Turnover Markers in Patients with Gaucher Disease Developing Osteonecrosis
Background/Objectives: Patients with Gaucher disease have a high risk of bone disease, with osteonecrosis representing the most debilitating complication. The pathogenesis of osteonecrosis has not been fully elucidated yet, and there is an unmet need for predictive biomarkers of bone complications. We aimed to assess the utility of angiogenesis and bone turnover biomarkers as predictors of osteonecrosis in Gaucher disease. Methods: Angiogenesis and bone turnover biomarkers were measured in 146 Gaucher disease patients (70M:76F, median age 49.5 [IQR 36.7 to 61]) with/without osteonecrosis enrolled in the UK-based registry GAUCHERITE [enrolment 2015–2017]. Receiver-operating characteristic curve analysis was used to compare the osteonecrosis predictive value of angiogenesis and bone turnover biomarkers and determine the optimal cut-off values for each biomarker. Results: Sixty-two patients had osteonecrosis before study enrolment, 11 had osteonecrosis during follow-up, and 73 remained osteonecrosis-free. Patients with osteonecrosis showed increased osteopontin and matrix metalloproteinase (MMP)-2 levels and decreased MMP-9 and vascular endothelial growth factor (VEGF)-C compared with those free from osteonecrosis. MMP-9 predicted future osteonecrosis with higher sensitivity and specificity (area under the receiver operating characteristic curve [AUC] 0.84 [95% CI 0.84–0.99]; sensitivity/specificity 82%/75%; cutoff value ≤ 72,420 pg/mL) than osteopontin, MMP-2 and VEGF-C when taken alone. The combination of MMP-9 and VEGF-C further increased the discriminating accuracy. Conclusions: The osteopontin–MMPs–VEGF axis is dysregulated in Gaucher disease patients with osteonecrosis. The combination of MMP-9 and VEGF-C circulating levels may serve to identify Gaucher disease patients at risk of osteonecrosis.
- Open Access
- 8 August 2024
- Published by BMJ in BMJ Case Reports
- Vol. 17 (8) , e259439
FGF23-secreting sinonasal tumour presenting with acute subdural haemorrhage and tumour-induced osteomalacia
A female in her 50s developed a headache, collapsed and was noted to have an acute atraumatic subdural haemorrhage (SDH) requiring surgical evacuation and intracranial pressure-directed therapy. Her background included recurrent epistaxis, severe generalised bone pain and multiple insufficiency fractures and an undifferentiated autoimmune connective tissue disease. Chronic hypophosphataemia, elevated alkaline phosphatase and raised fibroblast growth factor 23 (FGF23) were also noted. An MRI head and subsequent 68Ga CT/positron emission tomography scan demonstrated an intensely avid tumour in the right ethmoid sinus, extending intracranially. Phosphate was aggressively replaced, and alfacalcidol was initiated to circumvent the effects of FGF23 on her kidneys and bone minerals. The tumour was biopsied and then definitively resected via combined endonasal and craniotomy approaches, resulting in good clinical improvement. FGF23 titre and serum phosphate both normalised leaving the diagnosis of a phosphaturic mesenchymal tumour-secreting FGF23, leading to tumour-induced osteomalacia.
- 8 August 2024
- Published by BMJ in BMJ Case Reports
- Vol. 17 (8) , e259439
Open AccessFGF23-secreting sinonasal tumour presenting with acute subdural haemorrhage and tumour-induced osteomalacia
A female in her 50s developed a headache, collapsed and was noted to have an acute atraumatic subdural haemorrhage (SDH) requiring surgical evacuation and intracranial pressure-directed therapy. Her background included recurrent epistaxis, severe generalised bone pain and multiple insufficiency fractures and an undifferentiated autoimmune connective tissue disease. Chronic hypophosphataemia, elevated alkaline phosphatase and raised fibroblast growth factor 23 (FGF23) were also noted. An MRI head and subsequent 68Ga CT/positron emission tomography scan demonstrated an intensely avid tumour in the right ethmoid sinus, extending intracranially. Phosphate was aggressively replaced, and alfacalcidol was initiated to circumvent the effects of FGF23 on her kidneys and bone minerals. The tumour was biopsied and then definitively resected via combined endonasal and craniotomy approaches, resulting in good clinical improvement. FGF23 titre and serum phosphate both normalised leaving the diagnosis of a phosphaturic mesenchymal tumour-secreting FGF23, leading to tumour-induced osteomalacia.
- 1 April 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 307 (1) , e212779
Radiographic Cortical Thickness Index Predicts Fragility Fracture in Gaucher Disease
Reduced femoral cortical thickness index predicts future fragility fractures in Gaucher disease better than dual-energy x-ray absorptiometry. Background Patients with Gaucher disease (GD) have a high risk of fragility fractures. Routine evaluation of bone involvement in these patients includes radiography and repeated dual-energy x-ray a...
- 1 April 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 307 (1) , e212779
Radiographic Cortical Thickness Index Predicts Fragility Fracture in Gaucher Disease
Reduced femoral cortical thickness index predicts future fragility fractures in Gaucher disease better than dual-energy x-ray absorptiometry. Background Patients with Gaucher disease (GD) have a high risk of fragility fractures. Routine evaluation of bone involvement in these patients includes radiography and repeated dual-energy x-ray a...
- Open Access
PHOENIX (Picking up Hidden Osteoporosis Effectively during Normal CT Imaging without additional X-rays): protocol for a randomised, multicentre feasibility study
Introduction Two million out of the UK’s 5 million routine diagnostic CT scans performed each year incorporate the thoracolumbar spine or pelvic region. Up to one-third reveal undiagnosed osteoporosis or vertebral fractures. We developed an intervention, Picking up Hidden Osteoporosis Effectively during Normal CT Imaging without additional X-rays (‘PHOENIX’), to facilitate early detection and management of osteoporosis in people attending hospitals for CT scans. Methods and analysis A multicentre, randomised, pragmatic feasibility study. From the general CT-attending population, women aged ≥65 years and men aged ≥75 years attending for CT scans are invited to participate, via a novel consent form incorporating Fracture Risk Assessment (FRAX) questions. Those at increased 10-year risk (within the amber or red zones of the UK FRAX graphical outputs for further action) are block randomised (1:1:1) to (1) PHOENIX intervention, (2) active control or (3) usual care. The PHOENIX intervention comprises (i) retrieving the CT scans using the NHS Image Exchange Portal, (ii) Mindways QCT Pro software analysis of CT hip and spine none density with CT vertebral fracture assessment, (iii) sending the participants’ general practitioner (GP) a clinical report including diagnosis, necessary investigations and recommended treatment. Baseline CT scans from groups 2 and 3 are assessed with the PHOENIX intervention only at study end. Assuming 25% attrition, the study is powered to find a predicted superior osteoporosis treatment rate with PHOENIX (20%) vs 16% among patients whose GPs were sent the FRAX questionnaire only (active control) and 5% in the usual care group. Five hospitals are participating to determine feasibility. The co-primary feasibility outcome measures are (a) ability to randomise 375 patients within 10 months and (b) retention of 75% of survivors, completing their 1-year bone health outcome questionnaire. Secondary 1-year outcomes include osteoporosis/vertebral fracture identification rates and osteoporosis treatment rates. Stakeholder acceptability and economic aspects are evaluated. Ethics and dissemination Approved by committee (National Research Ethics Service) East of England (EE) as REF/19/EE/0176. Dissemination will be through the Royal Osteoporosis Society (to patients and public) as well as to clinician peers via national and international bone/rheumatology scientific and clinical meetings. Trial registration number ISRCTN14722819.
Open AccessPHOENIX (Picking up Hidden Osteoporosis Effectively during Normal CT Imaging without additional X-rays): protocol for a randomised, multicentre feasibility study
Introduction Two million out of the UK’s 5 million routine diagnostic CT scans performed each year incorporate the thoracolumbar spine or pelvic region. Up to one-third reveal undiagnosed osteoporosis or vertebral fractures. We developed an intervention, Picking up Hidden Osteoporosis Effectively during Normal CT Imaging without additional X-rays (‘PHOENIX’), to facilitate early detection and management of osteoporosis in people attending hospitals for CT scans. Methods and analysis A multicentre, randomised, pragmatic feasibility study. From the general CT-attending population, women aged ≥65 years and men aged ≥75 years attending for CT scans are invited to participate, via a novel consent form incorporating Fracture Risk Assessment (FRAX) questions. Those at increased 10-year risk (within the amber or red zones of the UK FRAX graphical outputs for further action) are block randomised (1:1:1) to (1) PHOENIX intervention, (2) active control or (3) usual care. The PHOENIX intervention comprises (i) retrieving the CT scans using the NHS Image Exchange Portal, (ii) Mindways QCT Pro software analysis of CT hip and spine none density with CT vertebral fracture assessment, (iii) sending the participants’ general practitioner (GP) a clinical report including diagnosis, necessary investigations and recommended treatment. Baseline CT scans from groups 2 and 3 are assessed with the PHOENIX intervention only at study end. Assuming 25% attrition, the study is powered to find a predicted superior osteoporosis treatment rate with PHOENIX (20%) vs 16% among patients whose GPs were sent the FRAX questionnaire only (active control) and 5% in the usual care group. Five hospitals are participating to determine feasibility. The co-primary feasibility outcome measures are (a) ability to randomise 375 patients within 10 months and (b) retention of 75% of survivors, completing their 1-year bone health outcome questionnaire. Secondary 1-year outcomes include osteoporosis/vertebral fracture identification rates and osteoporosis treatment rates. Stakeholder acceptability and economic aspects are evaluated. Ethics and dissemination Approved by committee (National Research Ethics Service) East of England (EE) as REF/19/EE/0176. Dissemination will be through the Royal Osteoporosis Society (to patients and public) as well as to clinician peers via national and international bone/rheumatology scientific and clinical meetings. Trial registration number ISRCTN14722819.